The Community As the Patient in Malaria-Endemic Areas: Preempting Drug Resistance with Multiple First-Line Therapies

Overview

Journal PLoS Med

Specialty General Medicine

Date 2016 Mar 30

PMID 27022739

Citations 34

Authors

Maciej F Boni

Nicholas J White

J Kevin Baird

Affiliations

Soon will be listed here.

Abstract

Maciej F. Boni and colleagues propose deploying multiple first-line combination therapies against malaria within a community to delay drug-resistance evolution.

Citing Articles

Recent updates in the WHO guidelines for malaria case management.

Adeel A Sudan J Paediatr. 2025; 24(2):155-163.

PMID: 39867284 PMC: 11757681. DOI: 10.24911/SJP.106-1729167507.

Geospatial Analysis of Malaria Burden in Kagera Region, Northwestern Tanzania Using Health Facility and Community Survey Data.

Petro D, Shaban N, Aaron S, Chacky F, Lazaro S, Boni M Open Forum Infect Dis. 2024; 11(11):ofae609.

PMID: 39507880 PMC: 11540141. DOI: 10.1093/ofid/ofae609.

Evaluation of Segmentation, Rotation, and Geographic Delivery Approaches for Deployment of Multiple First-Line Treatment (MFT) to Respond to Antimalarial Drug Resistance in Africa: A Qualitative Study in Seven Sub-Sahara Countries.

Audibert C, Aspinall A, Tchouatieu A, Hugo P Trop Med Infect Dis. 2024; 9(5).

PMID: 38787026 PMC: 11125622. DOI: 10.3390/tropicalmed9050093.

Combating antimicrobial resistance in malaria, HIV and tuberculosis.

Duffey M, Shafer R, Timm J, Burrows J, Fotouhi N, Cockett M Nat Rev Drug Discov. 2024; 23(6):461-479.

PMID: 38750260 DOI: 10.1038/s41573-024-00933-4.

Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in mainland Tanzania, 2019.

Ngasala B, Chiduo M, Mmbando B, Francis F, Bushukatale S, Makene T Malar J. 2024; 23(1):101.

PMID: 38594679 PMC: 11005286. DOI: 10.1186/s12936-024-04931-0.

References

Nosten F, van Vugt M, Price R, Luxemburger C, Thway K, Brockman A . Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet. 2000; 356(9226):297-302. DOI: 10.1016/s0140-6736(00)02505-8. View

Yeka A, Kigozi R, Conrad M, Lugemwa M, Okui P, Katureebe C . Artesunate/Amodiaquine Versus Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial. J Infect Dis. 2015; 213(7):1134-42. PMC: 4836737. DOI: 10.1093/infdis/jiv551. View

Peters W . The prevention of antimalarial drug resistance. Pharmacol Ther. 1990; 47(3):499-508. DOI: 10.1016/0163-7258(90)90067-c. View

Ter Kuile F, Nosten F, Thieren M, Luxemburger C, Edstein M, CHONGSUPHAJAISIDDHI T . High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J Infect Dis. 1992; 166(6):1393-400. DOI: 10.1093/infdis/166.6.1393. View

Bonhoeffer S, Lipsitch M, Levin B . Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci U S A. 1997; 94(22):12106-11. PMC: 23718. DOI: 10.1073/pnas.94.22.12106. View

Boni M, Smith D, Laxminarayan R . Benefits of using multiple first-line therapies against malaria. Proc Natl Acad Sci U S A. 2008; 105(37):14216-21. PMC: 2544604. DOI: 10.1073/pnas.0804628105. View

Carrara V, Zwang J, Ashley E, Price R, Stepniewska K, Barends M . Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One. 2009; 4(2):e4551. PMC: 2641001. DOI: 10.1371/journal.pone.0004551. View

Dondorp A, Nosten F, Yi P, Das D, Phyo A, Tarning J . Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009; 361(5):455-67. PMC: 3495232. DOI: 10.1056/NEJMoa0808859. View

Sabot O, Mwita A, Cohen J, Ipuge Y, Gordon M, Bishop D . Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania. PLoS One. 2009; 4(9):e6857. PMC: 2730578. DOI: 10.1371/journal.pone.0006857. View

10.

Talisuna A, Grewal P, Rwakimari J, Mukasa S, Jagoe G, Banerji J . Cost is killing patients: subsidising effective antimalarials. Lancet. 2009; 374(9697):1224-6. DOI: 10.1016/S0140-6736(09)61767-0. View

11.

Smith D, Klein E, McKenzie F, Laxminarayan R . Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty. Malar J. 2010; 9:217. PMC: 2916917. DOI: 10.1186/1475-2875-9-217. View

12.

Antao T, Hastings I . Policy options for deploying anti-malarial drugs in endemic countries: a population genetics approach. Malar J. 2012; 11:422. PMC: 3546853. DOI: 10.1186/1475-2875-11-422. View

13.

Sutherland C, Babiker H, Mackinnon M, Ranford-Cartwright L, El Sayed B . Rational deployment of antimalarial drugs in Africa: should first-line combination drugs be reserved for paediatric malaria cases?. Parasitology. 2011; 138(12):1459-68. PMC: 3575203. DOI: 10.1017/S0031182011001144. View

14.

Ursing J, Kofoed P, Rodrigues A, Blessborn D, Thoft-Nielsen R, Bjorkman A . Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial. J Infect Dis. 2010; 203(1):109-16. PMC: 3086436. DOI: 10.1093/infdis/jiq001. View

15.

. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of seventh biannual meeting (March 2015). Malar J. 2015; 14:295. PMC: 4524000. DOI: 10.1186/s12936-015-0787-z. View

16.

Nguyen T, Olliaro P, Dondorp A, Baird J, Lam H, Farrar J . Optimum population-level use of artemisinin combination therapies: a modelling study. Lancet Glob Health. 2015; 3(12):e758-66. PMC: 4641185. DOI: 10.1016/S2214-109X(15)00162-X. View

17.

Curtis C, Otoo L . A simple model of the build-up of resistance to mixtures of anti-malarial drugs. Trans R Soc Trop Med Hyg. 1986; 80(6):889-92. DOI: 10.1016/0035-9203(86)90248-8. View